1 / 14

Clinical Trial Commentary

PACT trial. Ross AM, et al. J Amer Coll Cardiol 1999;34:1954-1962. Reperfusion and LV function: rtPA vs placebo. PACT trial. Ross AM, et al. J Amer Coll Cardiol 1999;34:1954-1962. Adverse clinical outcomes: rtPA vs placebo. PACT trial. Ross AM, et al. J Amer Coll Cardiol 1999;34:1954-1962.

keaton
Download Presentation

Clinical Trial Commentary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and Vascular Biology at the Cleveland Clinic Dr Robert Califf Professor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University

    5. “The bottom line is that the combination therapy did not improve LV function or change outcome…Enhancing reperfusion by 10, 15, or 20 minutes hasn’t proven to be an added benefit. So why would you adopt that type of therapy?” Dr Cindy Grines William Beaumont Hospital, Detroit

    6. MUSTT trial eligibility criteria

    7. MUSTT:protocol

    8. MUSTT results

    9. MUSTT and implantable defibrillators

    10. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT): randomization

    11. SCD-HeFT eligibility criteria

    12. SCD-HeFT endpoints

    13. “…it is an implantable device. But if we had these results in a study looking at aspirin, do you really think we'd be sitting here arguing over would I withhold aspirin therapy from a defined sub-risk group…what we're really talking about here is economics, that's the bottom line.” Dr Eric Prystowski St Vincent Hospital

    14. CABG Patch trial eligibility criteria

    15. CABG Patch results

More Related